Regulation Tracker
Compounding pharmacy regulations explained
Two rules explain almost everything happening in this market: compounding requires a patient-specific need, and shortage resolution narrows what's permitted. Both are now biting.
Compounding is governed by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Two
rules explain nearly everything happening in this market right now.
Rule 1: Compounding requires a patient-specific need
A 503A pharmacy may compound a drug for an identified individual patient based on a
prescription documenting a clinical need the FDA-approved product can't meet — a different dose, an
allergy to an excipient, a format that doesn't exist commercially. Compounding is not a mechanism
for mass-producing cheaper copies of approved drugs.
This is the crux of the GLP-1 crackdown
The FDA's position, stated explicitly in 2026, is that compounding cannot be used to mass-market copies of
FDA-approved GLP-1s. When a provider markets a compounded drug as equivalent to Wegovy or Zepbound to an
undifferentiated audience, that's the conduct drawing warning letters — not the act of compounding
itself.
See the tracker →Rule 2: Shortages change what's permitted
While a drug is on the FDA shortage list, compounders have broader authority to produce copies of it.
That authority narrows when the shortage resolves. Both relevant shortages have now
resolved:
| Drug | Shortage resolved | Effect |
|---|
| Tirzepatide | December 19, 2024 | Compounding authority narrowed |
| Semaglutide | February 21, 2025 | Compounding authority narrowed |
This is the structural reason the compounded GLP-1 market is under pressure in 2026: the legal
justification that supported it at scale has been removed, and the FDA has said it intends to restrict
GLP-1 active ingredients used in mass-marketed non-approved compounded products.
What this means for you as a patient
Practical translation
Compounded GLP-1s remain available through providers operating on a patient-specific prescription basis.
But the regulatory ground is narrowing, prices in the brand market have fallen sharply, and the
cost/benefit of the compounded route is genuinely less obvious than it was 18 months ago. Price the
brand direct programs before defaulting to compounded.
503A vs 503B, in one line each
- 503A — traditional pharmacy, patient-specific prescription required, state-board
regulated, not cGMP. Nearly all telehealth peptide therapy.
- 503B — FDA-registered outsourcing facility, bulk production without
patient-specific Rx, cGMP-compliant, FDA-inspected. Mostly hospitals and clinics.
Full 503A vs 503B breakdown →
FAQ
Why is the FDA cracking down on compounded GLP-1s?
Because compounding is legally intended for patient-specific clinical needs, not for mass-producing cheaper copies of FDA-approved drugs. When the semaglutide and tirzepatide shortages resolved (Feb 2025 and Dec 2024), the broader compounding authority that supported the market at scale narrowed.
Can compounding pharmacies still make semaglutide?
Yes, on a patient-specific prescription basis where a clinician documents a need the approved product doesn't meet. What the FDA is targeting is mass-marketing compounded copies to an undifferentiated audience, and marketing claims implying equivalence to the approved drug.
Does this mean my provider will disappear?
Not necessarily — providers operating on a genuine patient-specific basis continue to operate. But the regulatory environment is tightening, and providers with weak compliance postures carry more risk. That's part of why we score pharmacy sourcing at 25%.
Medical disclaimer: Veritide is an independent consumer-research publication, not a healthcare provider or pharmacy. This page is informational and is not medical advice. Compounded medications are not FDA-approved as finished products. Always consult a licensed clinician before starting any peptide or GLP-1 therapy.